ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY?
https://doi.org/10.20996/1819-6446-2010-6-4-91-94
Abstract
The ACC/AHA clopidogrel clinical alert about the possibility of ineffective treatment with clopidogrel is discussed. The reason of this resistance to clopidogrel therapy and possible ways to overcome it is considered.
About the Author
S. J. Martsevich
State Research Center for Preventive Medicine,
I.M. Setchenov First Moscow State Medical University
Russian Federation
Russian Federation
Chair of Evidence Based Medicine
Petroverigsky per. 10, Moscow, 101990
References
1. HolmesD., Dehmer G., Kaul S. et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010;56(4):321-41.
2. Montalescot G., Wiviott S., Braunwald E. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double blind, randomised controlled trial. Lancet 2009; 373(9665): 723-731.
3. Storey R. Clopidogrel in acute coronary syndrome: to genotype or not? Lancet 2009; 373(9660): 276-278.
4. HulotJ.S.,Wuerzner G., Bachelot-Loza C. et al. Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. J Thromb Haemost 2010;8(3):610-3.
5. Cannon C., Harrington R., James S. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375(9711): 283-293.
6. Krasopoulos G., Brister S.J., BeattieW.S., Buchanan M.R.Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336(7637):195-8.
7. Gasparyan A.Y., Watson T., Lip G.Y. The role of aspirin in cardiovascular prevention: implications of aspirin resistance.J Am Coll Cardiol 2008; 51(19): 1829-1843.
8. Stone G.W. Ticagrelor in ACS: redefining a new standard of care? Lancet 2010; 375(9711): 263-265.
Review
For citations:
Martsevich S.J. ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? Rational Pharmacotherapy in Cardiology. 2010;6(4):607-609. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-4-91-94
Views:
599
Email this article 